We’re delighted to share the video and slide deck from our recent webinar featuring Dr. Dale Kempf (AbbVie), Dr. Ben Gold (Weill Cornell Medical College) and Dr. Peter Warner (Bill and Melinda Gates Foundation):
Tuberculosis (TB) is a terrible disease. Although there are first line and second line TB drugs, new medicines are urgently needed given both constantly emerging resistance, as well as the lengthy half-year regimens required for treatment.
An innovative collaboration going by the acronym TBDA (TB Drug Accelerator) is presented by AbbVie Distinguished Research Fellow Dr. Dale Kempf and Weill Cornell Medicine Associate Professor Dr. Ben Gold, moderated by the Gates Foundation Senior Program Officer Dr. Peter Warner. The TBDA brings together 7 major biopharmaceutical companies with leading academic, non-profit and government researchers to “identify new ways to target bacteria that are resistant to current drug regimens, develop new tools for drug discovery, and discover new drugs that can lead to accelerated treatments.”
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities.
CDD Vault: Drug Discovery Informatics your whole project team will embrace
Other posts you might be interested in
View All Posts
CDD Vault Updates
14 min
June 13, 2025
June Q2 2025 - Product Update Webinar: AI+ and Curves
Read More
CDD Blog
31 min
June 12, 2025
Top Scientific Data Platforms for AI-Driven Drug Discovery: What to Look For
Read More
CDD Blog
20 min
June 6, 2025
Synthetic Lethality in Precision Oncology: Integrating AI-Driven Discovery with Data Management Platforms
Read More